A comparative field trial of five measles vaccines produced in human diploid cell, MRC-5

Mirchamsy, H.; Shafyi, A.; Bahrami, S.; Kamali, Mohammad; Nazari, P.; Razavi, J.; Ahourai, P.; Fatemi, Seyed Reza; Amin-Salehi, M.

doi:10.1016/0092-1157(77)90014-2

Cited by 11 publications

(8 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These experiments were repeated in a comparative study with five attenuated measles vaccines produced in HDC. The clinical and serological responses of these vaccines in susceptible infants have been reported before (Mirchamsy et al 1977). The boosting effects of these vaccines are discussed in this report.…”

Section: Introductionmentioning

confidence: 84%

“…TV12, supplied by Dr S. Makino of Kitasato Institute, Tokyo, was an Enders-Edmonston virus which had been further attenuated by Makino, Sasaki & Nakamura (1973a,b). The history of its attenuation in sheep kidney cells and its adaptation to chick embryo culture has been published (Mirchamsy et al 1977).…”

Section: Measles Vaccines Made In Hdcmentioning

confidence: 99%

“…The blood was collected from finger pricks on filter paper disks as described previously (Mirchamsy et al 1968). Details of HI test have already been reported (Mirchamsy et al 1977). A fourfold or greater rise in HI titre was accepted as a significant increase.…”

Section: Serological Testingmentioning

confidence: 99%

See 2 more Smart Citations

Evaluation of live attenuated measles vaccines prepared in human diploid cells for reimmunization

et al. 1988

Self Cite

View full text Add to dashboard Cite

SUMMARYTwo live attenuated measles vaccines developed in baby calf kidney cells, a similar vaccine produced in chick embryo chorioallantoic cells and five vaccines prepared from human diploid cells (HDC) have been studied by subcutaneous injection in groups of susceptible and immune children in three field trials. The results indicated that the vaccine developed in chick embryo cells which caused mild clinical reactions, had induced a lower seroprotection rate in susceptible children and only a low rise in hemagglutination-inhibition (HI) antibody titre in previously immunized children. The serological responses induced by vaccines developed in HDC or in calf kidney cells were satisfactory in both susceptible and immune children. The superiority of HDC grown measles vaccine for revaccination is discussed.

show abstract

Section: Introductionmentioning

confidence: 84%

Section: Measles Vaccines Made In Hdcmentioning

confidence: 99%

See 1 more Smart Citation

Evaluation of live attenuated measles vaccines prepared in human diploid cells for reimmunization

et al. 1988

Self Cite

View full text Add to dashboard Cite

show abstract

“…This indicated that the AIK-C measles vaccine strain was stable and homogenous. The vaccines were evaluated in a field trial using seronegative children in Iran (18,19). The lowest clinical reactions to the AIK-C vaccine were compared to those of 5 other measles vaccine strains.…”

Section: Production and Comparative Study Of Aik-c/hdc (Mrc-5) Measlementioning

confidence: 99%

“…The control viruses for this study was the EdmonstonZagreb, adopted in human diploid cell (HDC) strain. In production and quality control of the measles vaccine, the safety, efficacy, neurovirulence, and genetic stability of the five measles vaccines were tested, based on WHO requirements (18). and all attenuated and virulent viruses, both before and after adaptation to HDC/MRC-5, were virulent in the baby hamsters except the Sugiyama virus.…”

Section: Production and Comparative Study Of Aik-c/hdc (Mrc-5) Measlementioning

confidence: 99%

Measles Vaccines in Iran: A 50-Year Review of Vaccine Development, Production and Effectiveness (1967 - 2017)

Shafyi

Mohammadi

2018

Jundishapur J Microbiol

View full text Add to dashboard Cite

Context: Information on the measles vaccine is important for future measles control policies. Vaccination history and laboratory confirmation during the development of the AIK measles vaccine in Iran is surveyed in this article. In addition, the production results and effectiveness of the Razi AIK-C/MRC-5 measles strain are compared with other vaccine strains.Evidence Acquisition: The current study was carried out to aim local measles vaccine manufacturing and consequences of that in Iran, using various search engines. Almost complete search carried out in medical databases including PubMed, Scopus, Web of Science, Scientific Information Database, IranMedex, Magiran and Google Scholar. Results: The morbidity rate of measles during the pre-vaccine era of this disease was 10,000 cases/year in 1970 -1972. In 1997, the rate was 24 in 1000 cases. After using the high quality Razi measles vaccine between 1995 and 2013, the number of measles-positive cases declined to a maximum of 35 cases per year, while the country's population increased by more than 2.5 times. The median of the Razi measles vaccine efficacy (VE) was > 92.1% compared with that of the pre-vaccine era. For patients who received 2 doses of the measles vaccine at either 6 and 12 months or 9 and 18 months of age, the median VEs were > 90.0% (interquartile range [IQR], 83% -97%) and 92.0% (IQR, 86% -98%), respectively. The age at vaccination and strain type used in the vaccines are reviewed in this article. Conclusion:The effectiveness of the local Razi measles vaccine resulted in a significant decline in measles mortality and morbidity in Iran. Two doses of the Razi measles (MR) or measles combination (MMR) vaccine provided excellent protection against measles. The seroprevalance of the measles vaccine in Iran revealed that more than 90% of Iranians are seropositive for the measles virus.

show abstract

Towards analyzing the potential of exosomes to deliver microRNA therapeutics

Giassafaki

Siqueira

Panteris

et al. 2020

Journal Cellular Physiology

View full text Add to dashboard Cite

Exosome selectivity mechanisms underlying exosome-target cell interactions and the specific traits affecting their capability to communicate still remain unclear. Moreover, the capacity of exosomes to efficiently deliver their molecular cargos intracellularly needs precise investigation towards establishing functional exosomebased delivery platforms exploitable in the clinical practice. The current study focuses on: (a) exosome production from normal MRC-5 and Vero cells growing in culture, (b) physicochemical characterization by dynamic light scattering (DLS) and cryo-transmission electron microscopy; (c) cellular uptake studies of rhodaminelabeled exosomes in normal and cancer cells, providing to exosomes either "autologous" or "heterologous" cellular delivery environments; and (d) loading exogenous Alexa Fluor 488-labeled siRNA into exosomes for the assessment of their delivering capacity by immunofluorescence in a panel of recipient cells. The data obtained thus far indicate that MRC-5 and Vero exosomes, indeed exhibit an interesting delivering profile, as promising "bio-shuttles," being pharmacologically exploitable in the context of theranostic applications.

show abstract

A comparative field trial of five measles vaccines produced in human diploid cell, MRC-5

Cited by 11 publications

References 8 publications

Evaluation of live attenuated measles vaccines prepared in human diploid cells for reimmunization

Evaluation of live attenuated measles vaccines prepared in human diploid cells for reimmunization

Measles Vaccines in Iran: A 50-Year Review of Vaccine Development, Production and Effectiveness (1967 - 2017)

Towards analyzing the potential of exosomes to deliver microRNA therapeutics

Contact Info

Product

Resources

About